CRISPR Therapeutics AG (NASDAQ:CRSP) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CRISPR Therapeutics AG | 60 | 0.00 | 34.37M | -0.46 | 0.00 |
| Brainstorm Cell Therapeutics Inc. | 4 | 0.00 | 18.67M | -0.98 | 0.00 |
Table 1 showcases the top-line revenue, earnings per share and valuation of CRISPR Therapeutics AG and Brainstorm Cell Therapeutics Inc.
Profitability
Table 2 shows CRISPR Therapeutics AG and Brainstorm Cell Therapeutics Inc.’s return on assets, return on equity and net margins.
| Net Margins | Return on Equity | Return on Assets | |
| CRISPR Therapeutics AG | 57,235,636.97% | -2.6% | -2% |
| Brainstorm Cell Therapeutics Inc. | 485,124,074.31% | 0% | -210.7% |
Liquidity
8.3 and 8.3 are the respective Current Ratio and a Quick Ratio of CRISPR Therapeutics AG. Its rival Brainstorm Cell Therapeutics Inc.’s Current and Quick Ratios are 0.4 and 0.4 respectively. CRISPR Therapeutics AG has a better chance of clearing its pay short and long-term debts than Brainstorm Cell Therapeutics Inc.
Analyst Recommendations
CRISPR Therapeutics AG and Brainstorm Cell Therapeutics Inc. Ratings and Recommendations are available on the next table.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| CRISPR Therapeutics AG | 0 | 0 | 3 | 3.00 |
| Brainstorm Cell Therapeutics Inc. | 0 | 0 | 1 | 3.00 |
The consensus target price of CRISPR Therapeutics AG is $72, with potential upside of 8.55%. Competitively Brainstorm Cell Therapeutics Inc. has a consensus target price of $9, with potential upside of 134.38%. Based on the analysts belief we can conclude, Brainstorm Cell Therapeutics Inc. is looking more favorable than CRISPR Therapeutics AG.
Insider & Institutional Ownership
Institutional investors owned 46.8% of CRISPR Therapeutics AG shares and 9.5% of Brainstorm Cell Therapeutics Inc. shares. CRISPR Therapeutics AG’s share owned by insiders are 0.4%. Comparatively, 10.4% are Brainstorm Cell Therapeutics Inc.’s share owned by insiders.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| CRISPR Therapeutics AG | 1% | 49.37% | 59.3% | 63.07% | 101.48% | 153.31% |
| Brainstorm Cell Therapeutics Inc. | -1.01% | 4.8% | -2.21% | 8.56% | 31% | 10.7% |
For the past year CRISPR Therapeutics AG was more bullish than Brainstorm Cell Therapeutics Inc.
Summary
On 6 of the 10 factors CRISPR Therapeutics AG beats Brainstorm Cell Therapeutics Inc.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.
